ARHGAP24: A Potential Drug Target and Biomarker (G83478)

Target Name: ARHGAP24

NCBI ID: G83478

ARHGAP24

ARHGAP24: A Potential Drug Target and Biomarker

Introduction

ARHGAP24 is a protein with a molecular weight of 73 kDa, which is located in the endoplasmic reticulum (ER) and has been identified as a potential drug target and biomarker. This protein plays a critical role in the regulation of cellular processes, including cell adhesion , migration, and invasion. It is a member of the RhoA GTPase family, which is known for their role in regulating various cellular processes, including cell growth, differentiation, and survival.

Drug Target Potential

ARHGAP24 has been identified as a potential drug target due to its unique structure and its involvement in cellular processes that are associated with various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. One of the key reasons for its potential as a drug target is its location in the ER, which is the protein synthesis and modification site for many drugs. Additionally, its involvement in cell adhesion and migration, as well as its role in regulating the delivery of cellular organelles, make it an attractive target for small molecules.

Biomarker Potential

ARHGAP24 has also been identified as a potential biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its involvement in these processes makes it a promising candidate for diagnostic and therapeutic applications. For example, ARHGAP24 has been shown to be overexpressed in various cancer types, which suggests that it may be a useful biomarker for cancer diagnosis and treatment. Additionally, its involvement in neurodegenerative diseases, such as Alzheimer's disease, has led to its potential as a biomarker for these conditions.

Understanding the Biology of ARHGAP24

The biology of ARHGAP24 is still being studied, but what is known is that it plays a critical role in the regulation of cellular processes, including cell adhesion, migration, and invasion. It is a member of the RhoA GTPase family, which is known for their role in regulating various cellular processes, including cell growth, differentiation, and survival.

ARHGAP24 is a 21-kDa protein that is located in the endoplasmic reticulum (ER). It is composed of a unique structure that consists of a catalytic GTPase domain and a cytoplasmic tail. The GTPase domain is responsible for the transfer of GTP to the GDP -bound GDP-clip complex, which is then translocated into the ER-associated protein (ERP) domain. The ERP domain is responsible for the regulation of ARHGAP24's activity.

In conclusion, ARHGAP24 is a protein with great potential as a drug target and biomarker. Its unique structure and its involvement in cellular processes that are associated with various diseases make it an attractive target for small molecules. Further research is needed to fully understand the biology of ARHGAP24 and its potential as a drug target and biomarker.

Protein Name: Rho GTPase Activating Protein 24

Functions: Rho GTPase-activating protein involved in cell polarity, cell morphology and cytoskeletal organization. Acts as a GTPase activator for the Rac-type GTPase by converting it to an inactive GDP-bound state. Controls actin remodeling by inactivating Rac downstream of Rho leading to suppress leading edge protrusion and promotes cell retraction to achieve cellular polarity. Able to suppress RAC1 and CDC42 activity in vitro. Overexpression induces cell rounding with partial or complete disruption of actin stress fibers and formation of membrane ruffles, lamellipodia, and filopodia. Isoform 2 is a vascular cell-specific GAP involved in modulation of angiogenesis

The "ARHGAP24 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ARHGAP24 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets